Association of aberrant expression of CD39 with the outcome of patients with cholangiocarcinoma. This is an ASCO Meeting Abstract from the ASCO Breakthrough: A Global Summit for Oncology Innovators.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results